Molecular biology of adenocarcinoma of the pancreatic duct, current state and future therapeutic avenues

Surgical Oncology

Volumn 22, Issue 2, 2013, Pages 69-76

  Abbas, Saleh ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Adenocarcinoma; Metastases; Molecular therapy; Pancreas; Targeted therapy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FOXM1 PROTEIN; GEMCITABINE; HISTONE DEACETYLASE 1; MATRIX METALLOPROTEINASE; MESOTHELIN; MICRORNA; NERVE CELL ADHESION MOLECULE; OSTEONECTIN; OSTEOPONTIN; PACLITAXEL; PROTEIN; PROTEIN P53; S100P PROTEIN; SONIC HEDGEHOG PROTEIN; TELOMERASE; UNCLASSIFIED DRUG; UVOMORULIN; VISMODEGIB;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; DEACETYLATION; DISTANT METASTASIS; DNA METHYLATION; ENZYME ACTIVITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; MITOGENESIS; ONCOGENE; PANCREAS ADENOCARCINOMA; PANCREATIC DUCT ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STROMA; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84878844436     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2012.12.002     Document Type: Review

References (87)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics CA Cancer J Clin 59 2009 225 249
2. P. Ghaneh, E. Costello, and J.P. Neoptolemos Biology and management of pancreatic cancer Gut 56 2007 1134 1152
3. P.J. Loehrer Sr., Y. Feng, H. Cardenes, L. Wagner, J.M. Brell, and D. Cella Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial J Clin Oncol 29 2011 4105 4112
4. R.A. Wolff Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas Curr Drug Targets 13 2012 781 788
5. A.A. Tentes, D. Kyziridis, S. Kakolyris, N. Pallas, G. Zorbas, and O. Korakianitis Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer Gastroenterol Res Pract 2012 506571
6. H. Haeno, M. Gonen, M.B. Davis, J.M. Herman, C.A. Iacobuzio-Donahue, and F. Michor Computational modeling of pancreatic cancer progression reveals dynamics of growth and dissemination and suggests optimum treatment strategies Cell 148 2012 362 375
7. C. Thierry, F. Desseigne, M. Ychou, and O. Bouché FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
8. S. Jones, X. Zhang, D.W. Parsons, J. Lin, R. Leary, and P. Angenendt Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 2008 1801 1806
9. C. Papageorgio, and M.C. Perry Epidermal growth factor receptor-targeted therapy for pancreatic cancer Cancer Invest 25 2007 647 657
10. J. Dancer, H. Takei, J.Y. Ro, and M. Lowery-Nordberg Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization Oncol Rep 18 2007 151 155
11. P.J. Campbell, S. Yachida, L.J. Mudie, P.J. Stephens, E.D. Pleas-ance, and L.A. Stebbings The patterns and dynamics of genomic instability in metastatic pancreatic cancer Nature 467 2010 1109 1113
12. A.J. Aguirre, C. Brennan, G. Bailey, R. Sinha, B. Feng, and C. Leo High resolution characterization of the pancreatic cancer Proc Natl Acad Sci US 101 2004 9067 9072
13. C.M. Ardito, B.M. Grüner, K.K. Takeuchi, C. Lubeseder-Martellato, N. Teichmann, and P.K. Mazur EGF receptor is required for KRAS-induced pancreatic tumourogenesis Cancer Cell 3 2012 304 317
14. G. Feldmann, R. Beaty, R.H. Hruban, and A. Maitra Molecular genetics of pancreatic intraepithelial neoplasia J Hepatobiliary Pancreat Surg 14 2007 224 232
15. A. Handra-Luca, C. Lesty, P. Hammel, A. Sauvanet, V. Rebours, and A. Martin Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma Pancreas 41 2012 416 421
16. E. Van Cutsem, H. van de Velde, and P. Karasek Phase III trial of gemcitabine plustipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430 1438
17. I. Tamm, B. Dorken, and G. Hartmann Antisense therapy in oncology: new hope for an old idea Lancet 358 2001 489 497
18. J. Rinehart, A.A. Adjei, and P.M. Lorusso Multicenter phase II study of the oral MEKinhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer J Clin Oncol 22 2004 4456 4462
19. P.A. Philip, J. Benedetti, and C. Fenoglio-Preiser Phase III study of gemcitabine [G]plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastaticpancreatic adenocarcinoma [PC]: SWOG S0205 study vol. 25 2007 4509, s.l.: ASCO Meeting Abstracts
20. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, and S. Gallinger Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966
21. D. Iannitti, T. Dipetrillo, and P. Akerman Erlotinib and chemoradiation followed bymaintenance erlotinib for locally advanced pancreatic cancer: a phase I study Am J Clin Onol 28 2005 470 577
22. E.S. Calhoun, J.B. Jones, R. Ashfaq, V. Adsay, S.J. Baker, and V. Valentine BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets Am J Pathol 163 2003 1255 1260
23. J.A. Wallace, G. Locker, and S. Nattam Sorafenib(S) plus gemcitabine (G) foradvanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium 4608, s.l. J Clin Oncol 25 2007 [Meeting Abstracts]
24. D. Ito, K. Fujimoto, and T. Mori In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer Int J Cancer 18 2006 2337 2343
25. O. Dormond, J.C. Madsen, and D.M. Briscoe Effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells J Biol Chem 282 2007 23679 23686
26. P. Tuncyurek, J.M. Mayer, and F. Klug Everolimus chemotherapy, and mycophenolate mofetilsensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard Eur Surg Res 39 2007 380 387
27. S.R. Alberts, N.R. Foster, and R.F. Morton PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study Ann Oncol 16 2005 1654 1661
28. C.A. Iacobuzio-Donahue, D.S. Klimstra, N.V. Adsay, R.E. Wilentz, P. Argani, and T.A. Sohn Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with convention Am J Pathol 157 2000 755 761
29. S. Yachida, and C.A. Iacobuzio-Donahue The pathology and genetics of metastatic pancreatic cancer Arch Pathol Lab Med 133 2009 413 422
30. C. Iacobuzio Donahue, B. Fu, S. Yachida, M. Luo, H. Abe, and C. Henderson DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J Clin Oncol 27 2009 1806 1813
31. C.H. Crane, G.R. Varadhachary, J.S. Yordy, G.A. Staerkel, M.M. Javle, and H. Safran Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dp) J Clin Oncol 29 2011 3037 3043
32. D.F. Peng, Y. Kanai, M. Sawada, S. Ushijima, N. Hiraoka, and T. Kosuge Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas Cancer Sci 96 2005 403 408
33. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales F A, Jones PA. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res;27:2291-8.
34. T. Ueki, M. Toyota, H. Skinner, K.M. Walter, C.J. Yeo, and J.P. Issa Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma Cancer Res 61 2001 8540 8546
35. A. Neesse, A. Hahnenkamp, H. Griesmann, M. Buchholz, S.A. Hahn, and A. Maghnouj Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions Gut 33 2012 1850 1854
36. A.C. Tan, A. Jimeno, S.H. Lin, J. Wheelhouse, F. Chan, and A. Solo-mon Characterizing DNA methylation patterns in pancreatic cancer genome Mol Oncol 3 2009 425 438
37. B. Klump, C.J. Hsieh, O. Nehls, S. Dette, K. Holzmann, and R. Kiesslich Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions Br J Cancer 88 2003 217 222
38. R. Dammann, U. Schagdarsurengin, L. Liu, N. Otto, O. Gimm, and H. Dralle Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma Oncogene 22 2003 3806 3812
39. S. Yonezawa, M. Higashi, N. Yamada, and M. Goto Precursor lesions of pancreatic cancer Gut Liver 2 2008 137 154
40. J.T. Xia, H. Wang, L.J. Liang, B.G. Peng, Z.F. Wu, and L.Z. Chen Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma Pancreas 41 2012 629 635
41. N.L. Tran, D.G. Adams, R.R. Vaillancourt, and R.L. Heimark Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization J Biol Chem 277 2002 32905 32914
42. Zhou W, Liang IC, Yee NS. Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development of cancer. Cancer Biol Ther;11:659-70.
43. P. García-Morales, A. Gómez-Martínez, A. Carrato, I. Martínez-Lacaci, V.M. Barberá, and J.L. Soto Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines Mol Cancer Ther 4 2005 1222 1230
44. C. Wray, K.F. Fournier, D. Sundi, L.M. Marquis, and D.J. McConkey Combination of proteasome- and histone deacetylase (HDAC) inhibitor treatment of pancreatic cancer Gastrointest Cancers Symp 2008 259
45. Ali Aghdassi Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer Gut 2011 10.1136/gutjnl-2011-300060
46. H.T. Lynch, C.A. Deters, C.L. Snyder, J.F. Lynch, P. Villeneuve, and J. Silberstein BRCA1 and pancreatic cancer: pedigree findings and their causal relationship Cancer Genet Cytogenet 158 2005 119 125
47. S.A. Hahn, B. Greenhalf, I. Ellis, M. Sina-Frey, H. Rieder, and B. Korte BRCA2, germline mutations in familial pancreatic carcinoma JNCI 95 2003 214 221
48. M.A. Lowery, D.P. Kelsen, Z.K. Stadler, K.H. Yu, Y.Y. Janjigian, and E. Ludwig An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions Oncologist 16 2011 1397 1402
49. M. van der Heijden, J. Brody, D. Dezentje, E. Gallmeier, S. Cunningham, and M. Swartz In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumour Clin Cancer Res 11 2005 508 7515
50. N. McCabe, C. Lord, A.N.J. Tutt, N.M.B. Martin, G.C.M. Smith, and A. Ashworth BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: an issue of potency Cancer Biol Ther 4 2005 934 936
51. S.K. Sandhu, T.A. Yap, and J.S. de Bono Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective Eur J Cancer 46 2010 9 20
52. D.P. Bartel MicroRNAs: genomics, biogenesis, mechanism, and function Cell 116 2004 281 297
53. S. Rachagani, S. Kumar, and S.K. Batra MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications Cancer Lett 292 2010 8 16
54. Y. Zhang, M. Li, H. Wang, W.E. Fisher, P.H. Lin, and Q. Yao MicroRNAs, profiling of 95 and analysis, in pancreatic cancer cell lines and surgical specimens by real-time PCR World J Surg 33 2009 698 709
55. N. Hanoun, Y. Delpu, A.A. Suriawinata, B. Bournet, C. Bureau, and J. Selves The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis J Clin Chem 56 2010 1107 1118
56. K.H. Lee, C. Lotterman, C. Karikari, N. Omura, G. Feldmann, and N. Habbe Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer Pancreatology 9 2009 293 301
57. D. Lodygin, V. Tarasov, A. Epanchintsev, C. Berking, T. Knyazeva, and H. Korner Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer Cell Cycle 7 2008 2591 2600
58. A. Li, N. Omura, S.M. Hong, A. Vincent, K. Walter, and M. Griffith Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels Cancer Res 70 2010 5226 5237
59. K. Nakata, K. Ohuchida, K. Mizumoto, T. Kayashima, N. Ikenaga, and H. Sakai MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis Surgery 150 2011 916 922
60. Q. Ji, X. Hao, M. Zhang, W. Tang, M. Yang, and L. Li MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating L-cells PLoS One 4 2009 e6816
61. C.W. Steele, K.A. Oien, C.J. McKay, and N.B. Jamieson Clinical potential of microRNAs in pancreatic ductal adenocarcinoma Pancreas 40 2011 1165 1171
62. P. Argani, C. Iacobuzio-Donahue, and B. Ryu Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 7 2001 3862 3868
63. R. Hassan, Z.G. Laszik, and M. Lerner Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis Am J Clin Pathol 124 2005 838 845
64. S.L. Swierczynski, A. Maitra, and S.C. Abraham Analysis and microarrays of novel tumor markers in pancreatic and biliary carcinomas using tissue Hum Pathol 35 2004 357 366
65. Raffit Hassana, and Mitchell Hob Mesothelin immunotherapy targeted cancer Eur J Cancer 44 2008 46 53
66. K. Uematsu, S. Kanazawa, and L. You Evidence of dishevelled overexpression and transcriptional activity of β-catenin Cancer Res 63 2003 4547 4551
67. N.G. Ordonez Application of mesothelin immunostaining in tumor diagnosis Am J Surg Pathol 27 2003 1418 1428
68. A. Rump, Y. Morikawa, and M. Tanaka Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion J Biol Chem 279 2004 9190 9919
69. D.G. Brockstedt, M.L. Leong, K.S. Bahjat, and L. Live-attenuated Monocytogenes encoding mesothelin for immunotherapy of patients with pancreas and ovarian cancer AACR Proc 2007 [Abstract #1874]
70. M.M. Javle, J.F. Gibbs, K.K. Iwata, Y. Pak, P. Rutledge, and J. Yu Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer Ann Surg Oncol 14 2007 3527 3533
71. Y. Masugi, K. Yamazaki, T. Hibi, K. Aiura, Y. Kitagawa, and M. Sakamoto Solitary cell infiltration is a novel indicator of poor prognosis and epithelial-mesenchymal transition in pancreatic cancer Hum Pathol 41 2010 1061 1068
72. Q. Yan, and E.H. Sage SPARC a matricellular glycoprotein with important biological functions J Histochem Cytochem 47 1999 1495 1506
73. N. Sato, N. Fukushima, N. Maehara, H. Matsubayashi, J. Koopmann, and G. Su SPARC/osteonectin and interactions is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal Oncogene 22 2003 5021 5030
74. N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, and A. Yang Increased antitumor activity intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin Cancer Res 12 2006 1317 1324
75. A.L. Collins, J. Rock, L. Malhotra, W.L. Frankel, and M. Bloomston Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma Ann Surg Oncol 2012 [Epub ahead of print.]
76. Sidney Kimmel. A phase II study of gemcitabine and nab-paclitaxel in combination with GDC-0449. ClinicalTrials.gov. http://clinicaltrials.gov/show/ NCT01088815NLMIdentifier:NCT01088815.
77. M. Bahra, C. Kamphues, S. Boas-Knoop, S. Lippert, U. Esendik, and U. Schüller Combination of hedgehog signaling blockage and chemotherapy leads to tumor reduction in pancreatic adenocarcinomas Pancreas 41 2012 222 229
78. K.E. Lines, C. Chelala, B. Dmitrovic, N. Wijesuriya, H.M. Kocher, and J.F. Marshall S100P-binding protein, S100PBP, mediates adhesion through regulation of cathepsin Z in pancreatic cancer cells Am J Pathol 180 2012 1485 1494
79. A.V. Biankin, J.G. Kench, E.K. Colvin, D. Segara, C.J. Scarlett, and N.Q. Nguyen Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer Gastroenterology 137 2009 558 568 68.e1-11
80. Y. Su, J. Li, A.K. Witkiewicz, D. Brennan, T. Neill, and J. Talarico N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer Oncogene 2011 10.1038/onc.2011.574
81. L.E. Jones, M.J. Humphreys, F. Campbell, J.P. Neoptolemos, and M.T. Boyd Comprehensiveanalysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancerincreased expression of matrix metalloproteinase-7 predicts poor survival Clin Cancer Res 10 2004 2832 2845
82. S.R. Bramhall, J. Schulz, J. Nemunaitis, P.D. Brown, M. Baillet, and J.A. Buckels A double blind placebo-controlled randomised study comparing gemcitabine and marimastat withgemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cnacer 87 2002 61 167
83. J. Okami, H. Yamamoto, and Y. Fujiwara Overexpression of cyclooxygenase-2 in pancreatic cancer Clin Cancer Res 5 1999 2018 2024
84. V. Ferrari, F. Valcamonico, and V. Amoroso Gemcitabine plus celecoxib (GECO) inadvanced pancreatic cancer: a phase II trial Cancer Chemother Pharmacol 57 2006 185 190
85. H. Ijichi, A. Chytil, A.E. Gorska, M.E. Aakre, B. Bierie, and M. Tada Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma J Clin Invest 121 2011 4106 4117
86. A. Balic, J. Dorado, M. Alonso-Gómez, and C. Heeschen Stem cells as the root of pancreatic ductal adenocarcinoma Exp Cell Res 318 2012 691 704
87. S.L. Bernhardt, M.K. Gjertsen, and S. Trachsel Telomerase peptide vaccination of patients with non-resectable pancreatic cancer, a dose escalating phase I/II study Cancer 95 2006 1474 1482